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Tumor necrosis factor (TNF)-related apoptosis-induc-
ing ligand (TRAIL) is a member of the TNF family that
interacts with several receptors, including TRAIL-R1,
TRAIL-R2, and TRAIL-R4. TRAIL-R1 and TRAIL-R2 can
induce apoptosis of cancer cells and activate the tran-
scription factor NF-kB. TRAIL-R4 can activate NF-kB
and protect cells from TRAIL-induced apoptosis. Here
we show that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-in-
duced NF-kB activation are mediated by a TRAF2-NIK-
IkB kinase a/b signaling cascade but is MEKK1 inde-
pendent. TRAIL receptors also activate the protein
kinase JNK. JNK activation by TRAIL-R1 is mediated by
a TRAF2-MEKK1-MKK4 but not the TRAF2-NIK/IkB ki-
nase a/b signaling pathway. We also show that activa-
tion of NF-kB or overexpression of TRAIL-R4 does not
protect TRAIL-R1-induced apoptosis. Moreover, inhibi-
tion of NF-kBb yI kBa sensitizes cells to tumor necrosis
factor- but not TRAIL-induced apoptosis. These findings
suggest that TRAIL receptors induce apoptosis, NF-kB
and JNK activation through distinct signaling path-
ways, and activation of NF-kB is not sufficient for pro-
tecting cells from TRAIL-induced apoptosis.
Tumor necrosis factor (TNF)
1-related apoptosis-inducing li-
gand (TRAIL) is a member of the TNF family, which also
includes TNF and FasL (1–3). Unlike TNF and FasL, which are
mainly expressed by activated immune cells, TRAIL is consti-
tutively expressed in most normal tissues (4, 5). Previous stud-
ies suggest that TRAIL is capable of inducing apoptosis of
various cancer cell lines but not of normal cells (3–5), pointing
to the possibility of developing TRAIL as a reagent for cancer
treatment.
TRAIL induces apoptosis through two receptors, TRAIL-
R1(DR4) (3, 6) and TRAIL-R2(DR5) (7–12). Both TRAIL-R1
and TRAIL-R2 contain a conserved cytoplasmic region called
“death domain” that is required for TRAIL-R1- and TRAIL-R2-
induced apoptosis. Three additional receptors, TRAIL-
R3(TRID/DcR1/LIT) (7, 10, 13, 14), TRAIL-R4 (15, 16), and
osteoprotegerin (17), also bind to TRAIL. TRAIL-R3 does not
have a cytoplasmic domain and can protect cells from TRAIL-
induced apoptosis, probably by functioning as a “decoy” recep-
tor (7, 10). TRAIL-R4 retains a cytoplasmic fragment contain-
ing one-third of the consensus death domain motif.
Overexpression of TRAIL-R4 activates the transcription factor
NF-kB and protects cells against TRAIL-induced apoptosis,
suggesting that TRAIL-R4, unlike TRAIL-R3, has a functional
intracellular signaling domain (15, 16). Thus, TRAIL-R4 may
protect cells from TRAIL-induced apoptosis by either acting as
a decoy receptor or transducing an anti-apoptotic signal. In this
context, several studies have established that NF-kB activation
can protect cells from TNF-induced apoptosis, probably
through its ability to induce the expression of anti-apoptosis
genes (18–20). In addition to TRAIL-R4, it has been shown
recently that TRAIL-R1 and TRAIL-R2 can also activate
NF-kB (8, 10, 21). These observations suggest that activation of
NF-kB alone is not sufficient to block apoptosis induced by
TRAIL receptors.
Currently, the intracellular signaling pathways responsible
for TRAIL receptor-mediated NF-kB activation are unclear,
and the mechanisms responsible for TRAIL receptor-induced
apoptosis are controversial. It has been reported that TRADD
and FADD, two death domain-containing cytoplasmic proteins
involved in TNF-R1 signaling, interact with TRAIL-R1 and
TRAIL-R2 and are involved in apoptosis mediated by these
receptors (8, 21). However, other studies have reached opposite
conclusions (6, 7, 10). Moreover, studies using FADD knockout
embryonic fibroblasts suggest that FADD is not required for
apoptosis induced by overexpression of TRAIL-R1 (22).
The signaling pathways mediated by TNF receptor family
members have been best illustrated by studies with TNF-R1.
TNF-R1 is a death domain-containing receptor that can induce
apoptosis and activate NF-kB and JNK kinase (23–26). The
death domain of TNF-R1 interacts with TRADD in a TNF-de-
pendent process (24, 25, 27). Once TRADD is recruited to
TNF-R1, it functions as an adapter protein to recruit several
structurally and functionally divergent proteins, including
FADD, RIP, TRAF2, and cIAP1 (25, 27, 28). The interaction of
TRADD with FADD leads to apoptosis through the activation
of a caspase cascade (24). The interaction of TRADD with
TRAF2 and RIP activates NIK, a member of the mitogen-
activated protein kinase kinase kinase family (29). Once NIK is
activated, it further activates two downstream kinases, IKKa
and IKKb (29–34). It has been shown that IKKa and IKKb
form a heterodimer complex that directly phosphorylates IkBs
(29–35). Once IkBs are phosphorylated, they are degraded, and
consequently the active NF-kB is released (36, 37).
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MEKK1, another member of the mitogen-activated protein ki-
nase kinase kinase family (26). Although it has been suggested
that overexpression of MEKK1 activates NF-kB (38), it is be-
lieved that under physiological conditions, MEKK1 mediates
TNF-R1-induced JNK but not NF-kB activation (35).
In this study, we investigated the mechanism of downstream
signaling by TRAIL receptors. The results indicate that
TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-kB activa-
tion are mediated by a TRAF2-NIK-IKKa/b-dependent signal-
ing cascade, whereas TRAIL-R1-induced JNK activation is me-
diated by a TRAF2-MEKK1-MKK4 dependent signaling
cascade. We also show that inhibition of TRAIL-R1-induced
NF-kB and JNK activation pathways does not block TRAIL-
R1-induced apoptosis. In addition, our data indicate that
NF-kB activation is not sufficient for protecting cells from
TRAIL-induced apoptosis.
EXPERIMENTAL PROCEDURES
Reagents and Cell Line—Recombinant human TRAIL was provided
by Dr. Bryant Darnay (University of Texas MD Anderson Cancer Cen-
ter, Houston, TX). The human embryonic kidney 293 cell line was
provided by Dr. Zaodan Cao (Tularik Inc., South San Francisco, CA).
Reporter Constructs and Mammalian Expression Vectors—The
NF-kB luciferase reporter construct (Dr. Gary Johnson, National Jew-
ish Center, Denver, CO), mammalian expression vectors encoding
TRAIL-R1 and TRAIL-R2 (Dr. Claudius Vincenz, University of Michi-
gan, Ann Arbor, MI), TRADD(296S) (Dr. Vijal Baichwal, Tularik Inc.,
South San Francisco, CA), FADD-(80–205), TRAF2-(87–501),
NIK(K429A/K430A), IKKa(K44A), IKKb(K44A), crmA (Dr. Dave Goed-
del, Tularik Inc., South San Francisco, CA), IkB(S32A/S36A) (Dr. T.
Kurama, Yamanuchi Pharmaceuticals Inc., Japan), MEKK1 (K1255M),
JNK1 (Dr. Gary Johnson, National Jewish Center, Denver, CO), and
MKK4-DN (Dr. David Riches, National Jewish Center, Denver, CO)
were obtained from the indicated sources.
TRAIL-R4 expression vector was constructed by replacing the
TRAIL-R1 cDNA in the pCMV1-Flag-DR4 (TRAIL-R1) vector (6) with a
polymerase chain reaction product of TRAIL-R4 cDNA. The parent
vector contains a DNA fragment encoding a signal peptide at 59 of the
Flag tag, and therefore the DNA fragment encoding the native N-
terminal signal peptide of TRAIL-R4 was omitted by polymerase chain
reaction.
Cell Transfection and Reporter Gene Assays—The human embryonic
kidney 293 cell line was maintained in high glucose Dulbecco’s modified
Eagle’s medium containing 10% fetal calf serum, 100 mg/ml penicillin G,
and 100 mg/ml streptomycin (Life Technologies, Inc.). For reporter gene
assays, ;2 3 10
5 cells/well were seeded on 6-well (35 mm) dishes. Cells
were transfected the following day by the standard calcium phosphate
precipitation method (39). Luciferase reporter assays were performed
using a luciferase assay kit (Pharmingen) following the manufacture’s
protocols.
Western Blotting—Western blots for detection of Flag-tagged TRAIL-
R1, TRAIL-R2, and TRAIL-R4 were performed with a monoclonal anti-
Flag following previously described procedure (27, 40).
Yeast Two-hybrid Screenings—The cDNA encoding the intracellular
domain of TRAIL-R1 was inserted in frame into the Gal4 DNA-binding
domain vector pGBT9 (CLONTECH). The human leukocyte, spleen,
and 293 cell two-hybrid cDNA libraries were also from CLONTECH.
The isolation of positive clones and subsequent two-hybrid interaction
analyses were carried out as described (23, 24, 28, 40).
Apoptosis Assays—293 cells were transfected with 0.1 mg of pCMV-
b-galactosidase plasmid and various amounts of indicated plasmids.
b-Galactosidase co-transfection assays for determination of cell death
were performed as described (23, 24, 28, 40). Transfected cells were
stained with X-gal as described previously (41). The number of blue
cells from four viewing fields in one well of a 35-mm dish was deter-
mined by counting under a microscope. The average number from one
representative experiment in which each transfection was done in du-
plicate is shown.
Solid-Phase Kinase Assays—Cytokine-treated or -transfected cells
were lysed with 600 ml of ice-cold lysis buffer (20 mM Tris (pH 7.5), 150
mM NaCl, 1% Triton X-100, 1 mM EDTA, 10 mg/ml aprotinin, 10 mg/ml
leupeptin, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, 2 mM
Na3VO4,a n d1m M dithiothreitol). The lysate was mixed with 15 mlo f
1:1 slurry of GST-c-Jun-Sepharose beads, and the mixture was incu-
bated at 4 °C for 1 h. The beads were then washed twice with lysis
buffer and once with kinase assay buffer (20 mM Hepes, pH 7.5, 10 mM
b-glycerophosphate, 10 mM p-nitrophenylphosphate, 10 mM MgCl2,1
mM dithiothreitol, 50 mM Na3VO4). The washed beads were resuspended
in 30 ml of kinase assay buffer containing 1 mlo f[ g-
32P]ATP (10 mCi/mL,
1C i5 37 GBq) and incubated at 30 °C for 30 min. The reaction was
terminated by the addition of 30 mlo f23 Laemmli sample buffer and
boiled for 5 min. The samples were fractionated by SDS-polyacrylamide
gel electrophoresis. The gels were washed in fixing buffer (10% acetic
acid, 30% methanol) three times, each for 10 min, and then dried.
Autoradiography was performed for 5–30 min. Fold induction of JNK
kinase activity was determined by phosphoimaging analysis.
Screening of TRAIL-resistant Cells—-HeLa or MCF7 cells (5 3 10
5)
were treated with 200 ng/ml recombinant TRAIL for 24 h. Treated cells
were switched to new medium containing 200 ng/ml TRAIL for addi-
tional 24 h. Surviving cells were then amplified and designated as
HeLa-TL-R and MCF7-TL-R, respectively.
RESULTS
Activation of NF-kB by TRAIL Receptors Is Mediated through
a TRAF2-NIK-IKKa/b-dependent Signaling Cascade—Al-
though several studies indicated that TRAIL could induce
NF-kB activation (8, 10, 21), one group reported results con-
trary to this (6). To determine whether TRAIL could activate
NF-kB, we transfected 293 cells with a NF-kB-luciferase re-
porter construct and performed luciferase reporter gene assays.
As shown in Fig. 1, treatment with recombinant soluble TRAIL
induced NF-kB activity. In this experiment, TRAIL was less
potent than TNF in activating NF-kB (Fig. 1). To determine the
relative contributions of various TRAIL receptors to TRAIL-
induced NF-kB activation, we compared the effects of overex-
pression of individual TRAIL receptors on NF-kB activity in
reporter gene assays. As shown in Fig. 2, TRAIL-R1, TRAIL-
R2, and TRAIL-R4 all activated NF-kB. TRAIL-R1 was found
to be more potent than TRAIL-R2 and TRAIL-R4 in activating
NF-kB in this experiment, at least partially because of its
higher expression level than TRAIL-R2 and TRAIL-R4 (Fig. 2).
Because TRAIL receptors have similar biological effects as
TNF receptors, we tested whether the cytoplasmic proteins
involved in TNF receptor signaling, including TRADD, TRAF2,
NIK, MEKK1, IKKa, and IKKb, also participate in TRAIL
receptor signaling. To do this, we determined whether their
dominant negative mutants could block TRAIL receptor-medi-
ated NF-kB activation in reporter gene assays. TRADD(296S),
FIG.1 .Activation of NF-kB by TRAIL. 293 cells (2 3 10
5) were
transfected with 0.5 mgo fN F - kB-luciferase reporter plasmid and 0.5 mg
of RSV-b-galactosidase plasmid as an internal control for transfection
efficiency. 14 h after transfection, cells were treated with 200 ng/ml
recombinant TRAIL, 20 ng/ml recombinant TNF, or left untreated for
8 h. Luciferase activity was measured using the luciferase assay kit
(Pharmingen) and normalized on the basis of b-galactosidase expres-
sion levels. Values are averages and standard deviations for a repre-
sentative experiment in which each transfection was performed in
duplicate. Data shown are relative luciferase activity compared with
the control treatment.
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mediated NF-kB activation (42) (Fig. 2D), did not block TRAIL-
R1-, TRAIL-R2-, and TRAIL-R4-induced NF-kB activation (Fig.
2), suggesting that TRADD is not involved in TRAIL receptor-
mediated NF-kB activation pathways. Consistent with this
observation, we failed to detect an interaction between TRADD
and TRAIL-R1, TRAIL-R2, or TRAIL-R4 in co-transfection and
co-immunoprecipitation experiments (data not shown). Inter-
estingly, overexpression of TRADD(296S) potentiated TRAIL
receptor-induced NF-kB activation (Fig. 2).
TRAF2-(87–501), a TRAF2 deletion mutant that has been
shown to block TNF-R2-induced NF-kB activation (43), po-
tently inhibited TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-in-
duced NF-kB activation (Fig. 2). Consistent with previous re-
ports (24, 43), TRAF2-(87–501) only weakly inhibited NF-kB
activation by overexpression of TNF-R1 (Fig. 2D) but potently
inhibited NF-kB activation by TNF ligation of endogenous
TNF-R1 in 293 cells.
2 These observations are consistent with
earlier reports (24, 43). The kinase-inactive mutants,
NIK(K429A/K430A), IKKa(K44A), and IKKb(K44A), which
have been shown to block TNF and interleukin 1-induced
NF-kB activation (28–34, 44), blocked TRAIL-R1-, TRAIL-R2-,
and TRAIL-R4-induced NF-kB activation (Fig. 2). As a positive
control, the kinase inactive NIK, IKKa, and IKKb mutants
inhibited TNF-R1-induced NF-kB activation. As expected,
IkBa(S32A/S36A), an IkBa mutant that cannot be phosphoryl-
ated and degraded and therefore has a constitutive inhibitory
effect on NF-kB (36, 37), completely inhibited TRAIL-R1-,
TRAIL-R2- and TRAIL-4-induced NF-kB activation (Fig. 2).
MEKK1(K1255M), a kinase inactive mutant of MEKK1 (45),
did not inhibit TRAIL-R4-induced NF-kB activation but par-
tially inhibited TRAIL-R1- and TRAIL-R2-induced NF-kB ac-
tivation (Fig. 3, A, C, and E). However, as MEKK1(K1255M)
inhibited basal NF-kB activity (Fig. 3, A, C, and E), the induc-
tion folds of NF-kB activation by TRAIL-R1, TRAIL-R2, and
TRAIL-R4 were actually higher in the presence of MEKK1-
(K1255M), compared with the control transfection with empty
vector (Fig. 3, B, D, and F). MEKK1(K1255M) also did not
inhibit TNF-R1-induced NF-kB activation (Fig. 3, G and H),
which is consistent with the belief that MEKK1 is not involved
in TNF-R1-induced NF-kB activation (35). This mutant, how-
ever, could potently inhibit TRAIL-R1-induced JNK activa-
tion (see below). These data suggest that MEKK1 is not
involved in TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced
NF-kB activation.
TRAIL Receptors Activate JNK through a TRAF2-MEKK1-
MKK4-dependent Pathway—Several TNF receptor family
members are capable of activating the JNK kinase pathway. To
determine whether TRAIL and its receptors have a similar
effect, we performed solid-phase kinase assays with GST-c-Jun
as a substrate. As shown in Fig. 4A, TRAIL treatment induced
JNK activation in 293 cells. Similarly, overexpression of
TRAIL-R1, TRAIL-R2, and TRAIL-R4 activated JNK (Fig. 4B)
and was further enhanced by TRAIL treatment. To explore the
possible signaling pathways leading to TRAIL receptor-in-
duced JNK activation, we tested whether the dominant nega-
tive mutants of TRAF2, NIK, MEKK1, MKK4, and IKKb could
block TRAIL-R1-induced JNK activation. As shown in Fig. 4C,
TRAF2-(87–501), MEKK1(K1255M), and the MKK4 dominant
negative mutant MKK4-DN inhibited TRAIL-R1-induced JNK
activation, whereas NIK(K429A/K430A) and IKKb(K44A) had
no significant inhibitory effect on TRAIL-R1-induced JNK ac-
tivation (Fig. 4C). These data suggest that TRAIL-R1-induced
JNK activation is mediated by a TRAF2-MEKK1-MKK4 de-
pendent pathway and is independent of the NIK-IKKa/b
cascade.
Because the above data indicated that TRAIL-R1-induced
NF-kB and JNK activation pathways might bifurcate at
TRAF2, we examined whether TRAF2 could directly interact
with TRAIL-R1 by co-transfection and co-immunoprecipitation
2 W.-H. Hu and H.-B. Shu, unpublished data.
FIG.2 .Activation of NF-kB by TRAIL receptors and effects of
various dominant negative mutants on TRAIL receptor-induced
NF-kB activation. For each transfection, 293 cells (2 3 10
5) were
transfected with 0.5 mgo fN F - kB-luciferase reporter plasmid, 0.5 mgo f
RSV-b-galactosidase, and 1 mg of pCMV1-TRAIL-R1 (A), 1 mgo f
pCMV1-TRAIL-R2 (B), 1 mg of pCVM1-TRAIL-R4 (C), 1 mg of pRK-
TNF-R1 (D), or 1 mg of empty control plasmid (E), together with 2 mgo f
the indicated dominant negative mutant plasmids or empty vector (2).
Control transfection (Control) contains equal amounts of NF-kB-lucif-
erase and RSV-b-galactosidase plasmids without TRAIL receptor ex-
pression plasmids and any mutant plasmids. For each transfection, 1
mg of crmA expression plasmid was added to protect cells from TRAIL-
R1-, TRAIL-R2-, and TNF-R1-induced apoptosis, and where necessary,
enough of an amount of empty control plasmid was added to keep each
transfection receiving the same amount of total DNA (5 mg). Luciferase
activity was measured 16 h after transfection and normalized on the
basis of b-galactosidase expression levels. Values are averages and
deviations for a representative experiment in which each transfection
was performed in duplicate. Data shown are relative luciferase activity
compared with the control transfection. The protein expression levels of
Flag-tagged TRAIL-R1, TRAIL-R2, and TRAIL-R4 in each transfection
are shown. 2, empty control vector; NIK(KK/AA), NIK(K429A/K430A);
IKKa(K/A), IKKa(K44A); IKKb(K/A), IKKb(K44A); IkB(SS/AA),
IkBa(S32A/S36A).
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TRAIL-R1, TRAIL-R2, and TRAIL-R4 (data not shown), sug-
gesting that unidentified adapter molecule(s) may link TRAF2
to TRAIL receptors.
FADD Is Involved in TRAIL-R1- and TRAIL-R2-induced Ap-
optosis Pathway—Previously, it has been reported that
TRAIL-R1 and TRAIL-R2 induce apoptosis through a FADD-
dependent pathway (8, 21). In contrast, other reports have
suggested that FADD is not involved in TRAIL-R1- and TRAIL-
R2-induced apoptosis (6, 7, 10, 23). We screened several human
cDNA libraries using the yeast two-hybrid system with
TRAIL-R1 intracellular domain as bait. These screenings iden-
tified FADD as a protein that specifically interacted with
TRAIL-R1 (data not shown). Consistent with the physical in-
teraction, FADD-(80–205), a dominant negative mutant of
FADD that inhibits TNF-R1-induced apoptosis (24), signifi-
cantly inhibited TRAIL-R1-induced apoptosis in a well estab-
lished apoptosis assay (23, 24, 28, 40) (Fig. 5A). These data
suggest that FADD is involved in a TRAIL-R1-induced apop-
tosis pathway.
FIG.3 . MEKK1 dominant negative
mutant does not inhibit TRAIL-R1-,
TRAIL-R2-, TRAIL-R4-, and TNF-R1-
induced NF-kB activation. For each
transfection, 293 cells (2 3 10
5) were
transfected with 0.5 mgo fN F - kB-lucifer-
ase reporter plasmid, 0.5 mg of RSV-b-
galactosidase, and 1 mg of the indicated
plasmid (1) or empty control vector (2).
For each transfection in A–D and G and
H,1mg of crmA expression plasmid was
added to protect cells from TRAIL-R1-,
TRAIL-R2-, and TNF-R1-induced apopto-
sis. Luciferase activity was measured
16 h after transfection and normalized on
the basis of b-galactosidase expression
levels. Values are averages and standard
deviations for a representative experi-
ment in which each transfection was per-
formed in duplicate. Data shown in A, C,
E, and G are relative luciferase activity
compared with the control transfection.
Data shown in B, D, F, and H are fold
induction of luciferase activity induced by
TRAIL-R1 (B), TRAIL-R2 (D), TRAIL-R4
(F), and TNF-R1 (H) in the presence of
empty control vector (Control)o r
MEKK1(K1255M).
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induced NF-kB and JNK Activation Pathways—Because
TRAIL-R1 is capable of inducing apoptosis and NF-kB and
JNK activation, we tested whether the signaling pathways
leading to the three distinct effects of TRAIL-R1 could cross-
talk. We transfected 293 cells with an expression vector for
TRAIL-R1 together with expression vectors for crmA, TRAF2-(87–
501), NIK(K429A/K430A), MEKK1(K1255M), IKKa(K44A),
IKKb(K44A), or IkBa(S32A/S36A). We found that overexpression
of TRAIL-R1 potently induced apoptosis. The caspase inhibitor
crmA inhibited TRAIL-R1-induced apoptosis (Fig. 5A). The mu-
tants TRAF2-(87–501), NIK(K429A/K430A), MEKK1 (K1255M),
IKKa(K44A), IKKb(K44A), and IkBa(S32A/S36A), which inhibited
TRAIL-R1-induced NF-kB and/or JNK activation, had no effect on
TRAIL-R1-induced apoptosis (Fig. 5A). These data suggest that
TRAIL-R1-induced apoptosis and NF-kB and JNK activation path-
ways are mediated through distinct pathways.
Activation of NF-kB Is Not Capable of Protecting Cells from
TRAIL-R1-induced Apoptosis—Although TRAIL induces apo-
ptosis of various cancer cells, some cancer cells and normal
cells are resistant to TRAIL-induced apoptosis, even though
these cells express TRAIL-R1 and TRAIL-R2 (3). Because
TRAIL-R1, TRAIL-R2, and TRAIL-R4 can activate NF-kB, one
of the possible mechanisms responsible for the resistance of a
cell to TRAIL may be because of a dominant effect of NF-kB
activation, which has been shown to protect cells from TNF-
induced apoptosis (18–20). In this context, it has been sug-
gested that TRAIL-R4, which can induce NF-kB activation but
not apoptosis, can protect cells from TRAIL-induced apoptosis
(16). To investigate whether NF-kB activation is responsible for
TRAIL-R4-mediated protection of cells from TRAIL-induced
apoptosis, we tested the effects of overexpression of TRAIL-R4
and up-regulation of NF-kB activity on TRAIL-R1-mediated
apoptosis. As shown in Fig. 5B, overexpression of TRAIL-R4
did not protect TRAIL-R1-induced apoptosis. Co-transfection of
293 cells with expression vectors for TRAIL-R1 and NIK or
IKKb greatly increased NF-kB activity in comparison to
TRAIL-R1 transfection alone (Fig. 5C). However, up-regulation
of NF-kB activity by overexpressing NIK and IKKb had no
protective effect on TRAIL-R1-induced apoptosis (Fig. 5B).
These data suggest that overexpression of TRAIL-R4 and acti-
vation of NF-kB do not protect cells from TRAIL-R1-induced
apoptosis.
Inhibition of NF-kB Activation Potentiates TNF-, but Not
TRAIL-induced Apoptosis—IkBa(S32A/S36A) is an IkBa mu-
tant that has more potent inhibitory effect on NF-kB activation
than its wild type counterpart (36, 37). To test whether inhibi-
tion of NF-kB activation can sensitize cells to TRAIL, we de-
termined the effect of IkBa(S32A/S36A) on TRAIL-induced ap-
optosis. To do this, we first isolated TRAIL-resistant HeLa and
MCF7 cells. In these experiments, 90% of HeLa cells and 30%
of MCF7 cells were killed. TRAIL-resistant cells, designated as
HeLa-TL-R and MCF7-TL-R, respectively, were then amplified
and transfected with expression vectors for IkBa(S32A/S36A)
and a b-galactosidase reporter gene. Fourteen hours after
transfection, the cells were treated with TNF, TRAIL, or left
untreated for 10 h and then stained by X-gal. As shown in Fig.
6, transfection of IkBa(S32A/S36A) sensitized both HeLa-TL-R
and MCF7-TL-R cells to TNF- but not TRAIL-induced apopto-
sis. These data are consistent with the hypothesis that activa-
tion of NF-kB protects TNF- but not TRAIL-induced apoptosis.
DISCUSSION
TRAIL stimulation induces three distinct biological effects:
apoptosis, NF-kB, and JNK activation. These effects of TRAIL
are mediated through three signaling receptors, including
TRAIL-R1, TRAIL-R2, and TRAIL-R4. In this report, we inves-
tigated the mechanisms of downstream signaling by the three
mentioned TRAIL receptors.
TNF-R1 is a prototypic member of the TNF receptor family,
which activates NF-kB through a TRADD-TRAF2/RIP-NIK-
IKKa/b-dependent signaling cascade (23–37). In this study, we
found that TRADD did not interact with the TRAIL receptors.
A dominant negative mutant of TRADD, which blocks TNF-R1-
induced NF-kB activation (42) (Fig. 2), did not inhibit TRAIL-
R1-, TRAIL-R2-, and TRAIL-R4-induced NF-kB activation. Our
results are consistent with the reports that TRAIL-R1 and
TRAIL-R2 do not interact with TRADD (6, 7) but contradict
certain reports that TRAIL-R1 and TRAIL-R2 interact with
TRADD in co-transfection/co-immunoprecipitation experi-
FIG.4 . TRAIL receptors activate JNK activity through a
TRAF2-MEKK1-MKK4-dependent signaling pathway. A, TRAIL
induces JNK kinase activity. 293 cells (5 3 10
5) were treated with 20
ng/ml TNF, 100 ng/ml TRAIL, or left untreated for 30 min. Cell were
then lysed, and JNK activity in the lysate was measured by a solid-
phase kinase assay using recombinant GST-c-Jun as a substrate. The
relative fold induction in JNK activity was determined by phosphoim-
aging and is indicated at the bottom of each lane. Data shown are from
one representative experiment. B, TRAIL-R1, TRAIL-R2, and
TRAIL-R4 induce JNK kinase activity. 293 cells (8 3 10
5) were trans-
fected with 1 mg of JNK1 expression plasmid, together with 5 mgo f
empty control vector, TRAIL-R1, TRAIL-R2, or TRAIL-R4. 5 mg of crmA
expression plasmid were added to each transfection to inhibit cell
death. 16 h after transfection, cells were lysed, and JNK activity in the
lysate was determined by a solid-phase kinase assay using recombinant
GST-c-Jun as a substrate. Indicated at the bottom are relative induc-
tion folds in JNK activities that were normalized based on their relative
expression levels to TRAIL-R1. The expression levels of the tranfected
receptors are shown in the lower panel. Data shown are from one
representative experiment. C, inhibition of TRAIL-R1-induced JNK
activity by dominant negative mutants of TRAF2, MEKK1, and MKK4
but not by those of NIK and IKKb. 293 cells (2 3 10
5) were transfected
with 3 mg of empty control vector (lane 1)o r1mg of TRAIL-R1 expres-
sion plasmid together with 2 mg of plasmid indicated at the top of the
figure. 1 mg of crmA expression plasmid was added to inhibit cell death.
16 h after transfection, cells were lysed, and JNK activity in the lysate
was determined by a solid-phase kinase assay using recombinant GST-
c-Jun as a substrate. The relative fold induction in JNK activity was
determined by phosphoimaging and is indicated at the bottom of each
lane.
Signaling by TRAIL Receptors 30607ments (8, 21), and a TRADD deletion mutant inhibits
TRAIL-R1 and TRAIL-R2-induced NF-kB activation (21). It
should be pointed out that the interaction observed by the later
two reports was weak, and their co-immunoprecipitation ex-
periments did not have a nonspecific antibody control (8, 21). In
addition, one group used only the intracellular domains of
TRAIL-R1 and TRAIL-R2, but not full-length receptor proteins,
in their co-immunoprecipitation experiments (8). The TRADD
deletion mutant used by Chaudhary et al. (21) itself activates
NF-kB and, therefore, is not strictly a dominant negative mu-
tant. In fact, we found that TRADD(296S), a well characterized
dominant negative mutant of TRADD (42), potentiated TRAIL
receptor-induced NF-kB activation. Currently, the mechanism
responsible for this observation is not clear.
In this study, we found that TRAIL-R1-, TRAIL-R2-, and
TRAIL-R4-induced NF-kB activation was potently inhibited by
TRAF2-(87–501), NIK(K429A/K430A), IKKa(K44A), and
IKKb(K44A), but not by MEKK1(K1255M), suggesting that
TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-kB activa-
tion is mediated by a TRAF2-NIK-IKKa/b-dependent signaling
cascade and is independent of MEKK1.
Our studies indicate that TRAIL-R1, TRAIL-R2, and
TRAIL-R4 are also capable of inducing JNK kinase activity
(Fig. 4). TRAIL-R1-induced JNK activation can be inhibited by
dominant negative mutants of TRAF2, MEKK1, and MKK4 but
not by those of NIK and IKKb. Therefore, TRAIL-R1-induced
JNK activation is mediated by a TRAF2-MEKK1-MKK4 de-
pendent pathway and is independent of the NIK-IKK kinase
cascade. These data suggest that TRAIL-R1-induced NF-kB
and JNK activation pathways bifurcate at TRAF2. Because
TRAF2 does not directly interact with TRAIL-R1, TRAIL-R2,
and TRAIL-R4, whereas FADD is not involved in TRAIL recep-
tor-mediated NF-kB activation pathway, we believe that uni-
dentified adapter proteins other than TRADD and FADD are
required for recruiting TRAF2 to TRAIL-R1, TRAIL-R2, and
TRAIL-R4 signaling complexes.
In addition to NF-kB and JNK activation, TRAIL-R1 can
potently induce apoptosis. The pathway leading to TRAIL-R1-
induced apoptosis, however, remains controversial. We
screened yeast two-hybrid libraries with the intracellular do-
main of TRAIL-R1 as bait and identified FADD as a protein
that specifically interacted with TRAIL-R1.
2 Furthermore, a
FADD dominant negative mutant significantly inhibited
TRAIL-R1-induced apoptosis in 293 cells (Fig. 5A). Our data
support the hypothesis that FADD is involved in TRAIL-R1-
induced apoptosis pathway.
FIG.5 . TRAIL-R1-induced apopto-
sis is blocked by a FADD dominant
negative mutant but not affected by
inhibition or up-regulation of NF-kB
activation. A, effects of crmA and vari-
ous mutant proteins on TRAIL-R1-in-
duced apoptosis. B, overexpression of
TRAIL-R4 and up-regulation of NF-kB ac-
tivity do not protect cells from TRAIL-R1-
induced apoptosis. C, up-regulation of
NF-kB activity by overexpression of NIK
and IKKb. 293 cells (2 3 10
5) were trans-
fected with 1 mg of pCMV1-TRAIL-R1
(white bars) or empty control plasmid
(black bars), 0.1 mg of pCMV-b-galactosid-
ase plasmid, 0.5 mgo fN F - kB luciferase
reporter plasmid, and 2 mg of one of the
indicated expression plasmids. 16 h after
transfection, cells in two wells were
stained by X-gal and surviving blue cells
were counted under a microscope as de-
scribed (23, 24, 28, 40) (A and B). Cells in
other two wells were collected for meas-
urement of luciferase activities (C). Data
shown are averages and standard devia-
tions for a representative experiment.
Signaling by TRAIL Receptors 30608Previously, it has been shown that overexpression of
TRAIL-R1 can induce apoptosis in FADD(2/2) embryonic fi-
broblasts (22), suggesting that FADD is dispensable for TRAIL-
R1-induced apoptosis. However, these experiments can not ex-
clude the possibility that FADD is required for apoptosis
induced by ligation of TRAIL-R1 with TRAIL in untransfected
cells. For example, the death domain containing TRAIL-R1,
when overexpressed, may artificially interact with other death
domain-containing proteins, such as RIP, and therefore induce
apoptosis in FADD(2/2) cells. Alternatively, a FADD-like mol-
ecule, which may have higher affinity with TRAIL-R1, can also
transduce the death signal from TRAIL-R1 to the downstream
caspase cascades.
In our studies, we also found that TRAF2-(87–501), NIK(K429A/
K430A), IKKa(K44A), IKKb(K44A), MEKK1(K1255M), and
IkBa(SS/AA), the mutants which blocked TRAIL receptor-induced
NF-kB and/or JNK activation (Figs. 2 and 4), did not inhibit
TRAIL-R1-induced apoptosis (Fig. 5). These data suggest that
TRAIL-R1 induces apoptosis, NF-kB, and JNK activation through
distinct pathways.
Previous studies indicate that TRAIL-R4 can protect cells
from TRAIL-induced apoptosis. At least two hypotheses have
been proposed to explain this observation. First, TRAIL-R4
may function as a decoy receptor for TRAIL-induced apoptosis,
for example, by competing with TRAIL-R1 and TRAIL-R2 for
TRAIL binding. This hypothesis, however, cannot explain the
observations that some TRAIL-sensitive cells express both
TRAIL-R3 and TRAIL-R4, whereas some TRAIL resistant cells
do not have detectable TRAIL-R3 and TRAIL-R4 (3). Second,
TRAIL-R4 may activate a protective signal to inhibit TRAIL-
induced apoptosis, for example, by activating NF-kB. Previ-
ously, it has been shown that activation of NF-kB can inhibit
TNF-induced apoptosis, probably through transcriptional in-
duction of apoptosis inhibitory genes (20). However, this hy-
pothesis is complicated by the fact that stimulation of
TRAIL-R1 and TRAIL-R2 simultaneously activates NF-kB and
induces apoptosis. One can argue that NF-kB activity induced
by TRAIL-R1 and TRAIL-2 is too low to antagonize the domi-
nant apoptotic effect induced by TRAIL-R1 and TRAIL-R2. In
this study, we found that overexpression of TRAIL-R4 did not
protect cells from apoptosis induced by TRAIL-R1. In addition,
a dramatic up-regulation of NF-kB activity by overexpressing
NIK and IKKb had no significant effect on TRAIL-R1-induced
apoptosis (Fig. 5). Moreover, inhibition of NF-kB activation by
an IkBa mutant, IkBa(S32A/S36A), sensitized cells to TNF-
but not TRAIL-induced apoptosis (Fig. 6). These data suggest
that activation of NF-kB is not sufficient for protecting cells
from TRAIL-induced apoptosis, and an alternative mechanism
other than NF-kB activation may account for the protective
role of TRAIL-R4 on TRAIL-induced apoptosis.
In conclusion, our data indicate that TRAIL induces apopto-
sis, NF-kB activation, and JNK activation through distinct
pathways (Fig. 7). We also conclude that NF-kB activation is
not sufficient for protecting cells from TRAIL-induced
apoptosis.
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